| Literature DB >> 28379727 |
Jill M Pulley1, Jana K Shirey-Rice1, Robert R Lavieri1, Rebecca N Jerome1, Nicole M Zaleski1, David M Aronoff2,3, Lisa Bastarache4, Xinnan Niu4, Kenneth J Holroyd1,5, Dan M Roden6, Eric P Skaar7, Colleen M Niswender8,9, Lawrence J Marnett10,11, Craig W Lindsley10,12, Leeland B Ekstrom1,13, Alan R Bentley5, Gordon R Bernard1,6, Charles C Hong14,15, Joshua C Denny4.
Abstract
The potential impact of using human genetic data linked to longitudinal electronic medical records on drug development is extraordinary; however, the practical application of these data necessitates some organizational innovations. Vanderbilt has created resources such as an easily queried database of >2.6 million de-identified electronic health records linked to BioVU, which is a DNA biobank with more than 230,000 unique samples. To ensure these data are used to maximally benefit and accelerate both de novo drug discovery and drug repurposing efforts, we created the Accelerating Drug Development and Repurposing Incubator, a multidisciplinary think tank of experts in various therapeutic areas within both basic and clinical science as well as experts in legal, business, and other operational domains. The Incubator supports a diverse pipeline of drug indication finding projects, leveraging the natural experiment of human genetics.Entities:
Keywords: BioVU; PheWAS; genetics; repurposing; translational research
Mesh：
Year: 2017 PMID： 28379727 PMCID： PMC5399743 DOI： 10.1089/adt.2016.772
Source DB: PubMed Journal: Assay Drug Dev Technol ISSN： 1540-658X Impact factor: 1.738